CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027
Candel said it is in continuing dialogue with the FDA regarding the Biologics License Application (BLA) submission for aglatimagene in intermediate- to high-risk localized prostate cancer.